Type 1 diabetes is not caused by sugar, nor lifestyle, nor anything a child could have done differently. It is the immune system — our body's defender — quietly mistaking the pancreas for an invader, and spending months silently destroying the cells that keep us alive. This is what we know, what we don't, and who is racing to fix it.
Every cell in your body runs on glucose. Insulin is the key that unlocks the door. In Type 1 diabetes, the factory that makes the key — a cluster of beta cells tucked inside the pancreas — is demolished by the immune system. The doors stay locked. Glucose piles up in the blood. Cells, starved, begin to cannibalize fat for fuel, releasing acidic byproducts that, untreated, kill within weeks.
For most of human history, Type 1 diabetes was an obituary with a countdown. The only question was how long. The story below spans the Ebers Papyrus to CRISPR — every dot a life extended.
Ancient Egyptian physicians describe a mysterious condition of "too-great emptying of urine" — the first written record of what we now recognize as diabetes. Treatment: wheat grains, lead, and earth.
Greek physician Aretaeus of Cappadocia names the condition, observing that patients seemed to melt away into their own urine. The name sticks for two millennia.
Two German researchers remove a dog's pancreas to study digestion. The dog develops diabetes. The source of the disease, after thousands of years, has an address.
The missing pancreatic substance gets a name — from the Latin insula, for island, after the pancreatic islet cells it was presumed to come from. Finding it is another matter.
In a Toronto lab, a Canadian surgeon, a medical student, a professor, and a biochemist isolate insulin from dog pancreases. Early batches look like "thick brown muck." Collip purifies it.
January 11th. A dying Toronto teenager weighing 29kg receives the world's first human insulin injection. The first dose, impure, fails. Twelve days later, a purer dose restores him. Banting and Macleod receive the Nobel Prize within 18 months — still the fastest ever for a medical breakthrough.
Banting, Best and Collip sell their insulin patent to the University of Toronto for a single dollar each. They want no one excluded by price. Eli Lilly begins mass production.
Genentech engineers E. coli to produce human insulin — the first commercial recombinant-DNA drug. By 1982, Humulin replaces the cow and pig pancreases that had been supplying the world.
The first CGM is approved. Instead of pricking a finger 6 times a day, a sensor under the skin reads glucose every few minutes. Combined with pumps, this eventually becomes an "artificial pancreas."
The FDA approves the first drug that can delay the onset of Type 1 diabetes in at-risk patients by an average of two years. Not a cure — but the first time we intervened upstream of the attack.
A 25-year-old woman in China, infused with islet cells grown from her own reprogrammed stem cells, begins producing her own insulin again — becoming the first person functionally cured by stem-cell therapy. Vertex Pharma announces similar results in 12 more.
Stanford researchers cure autoimmune diabetes in every mouse they try, using a gentle blood-stem-cell plus islet transplant. Translation to humans now within reach. The 104-year story continues.
"We need not insulin, but the cells that make it."— Douglas Melton, Harvard Stem Cell Institute
Replacing insulin kept people alive — but did nothing to stop the immune attack, restore the pancreas, or match the exquisite moment-to-moment precision of a healthy body. Every cure attempt has had to solve at least three of these problems at once.
Even if you grew a whole new pancreas, the immune system — trained to see beta cells as enemies — would destroy it again. You have to re-educate immunity itself.
Too little: organs fail over years. Too much: brain damage within minutes. A healthy pancreas dosed by milligrams, per second. A syringe can only approximate.
A virus? A gut bacterium? A random recombination in the thymus? A century of studies points in many directions. Without a cause, prevention stays out of reach.
Other organs regenerate. Beta cells barely do. Growing enough of them in a lab — billions, the same size, the same behavior — is an industrial problem nearly as hard as the biological one.
We can transplant islet cells from organ donors today — but recipients must take immunosuppressants for life, swapping diabetes for vulnerability to infection and cancer. A half-cure.
Without a functioning pancreas, every meal, every workout, every night of sleep becomes a calculation. Below: one real day's blood glucose for a person with T1D (anonymized, hypothetical reconstruction), versus the narrow band a healthy body holds without you ever noticing.
For the first time in 104 years, the question has shifted from can we manage this to can we end it. Below is a snapshot of the labs and companies with the most momentum as of 2025–2026.
Their therapy VX-880 grows insulin-producing islet cells from embryonic stem cells and infuses them into patients. First-in-human trials show sustained insulin production in 12 people — the first real demonstration of stem-cell replacement for T1D.
In 2024, reprogrammed a 25-year-old patient's own cells into islets and implanted them. She is the first person cured by her own stem cells — no donor, no rejection, no lifelong immunosuppression needed.
A gentle blood-stem-cell + islet transplant that builds a hybrid immune system — donor + recipient — and stops the autoimmune attack at its source. Cured 19/19 diabetic mice in 2025. Tools already exist clinically; human trials next.
The first drug ever to delay the onset of T1D in at-risk children. A 14-day IV course blunts the T-cell attack and buys patients, on average, an extra 2+ years before insulin dependence.
Engineering regulatory T-cells (Tregs) with chimeric antigen receptors (CARs) that act as bodyguards — guarding transplanted islet cells from autoimmune destruction without systemic immunosuppression.
£50M global push funding 23 projects across 49 institutions in 8 countries. Focus: glucose-responsive "smart" insulins that activate only when sugar is high, plus insulin-glucagon hybrids that prevent dangerous lows.
Research concentrates in the US, Canada, UK and China. Care — and access to modern insulin — does not. In parts of sub-Saharan Africa, life expectancy after diagnosis can still be measured in months. The century since Banting has unevenly reached everyone.
The story began with a surgeon waking at 2 a.m. to scribble a hypothesis, and a 14-year-old boy given a second chance on a Toronto hospital ward. It continues now — in South Carolina, in Palo Alto, in a small lab in Beijing — with scientists trying not just to treat the body's accidental war on itself, but to end it.
The finish line moves. So do they.